NRC Health (National Research Corporation) - Q3 2024 10-Q Summary
Business Context and Reporting Period
NRC Health is a provider of analytics and insights for healthcare organizations, focusing on patient and employee experience. This report covers the quarterly period ended September 30, 2024. The company operates primarily in the United States and recently dissolved its Canadian subsidiary in August 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $35.82 million | $37.95 million | $106.15 million | $110.58 million |
| Net Income | $5.69 million | $7.88 million | $18.22 million | $22.11 million |
| Operating Income | $7.98 million | $9.96 million | $25.61 million | $28.34 million |
| Operating Margin | 22% | 26% | 24% | 26% |
| Diluted EPS | $0.24 | $0.32 | $0.76 | $0.89 |
| Cash from Operations (YTD) | $28.25 million (2024) vs $26.41 million (2023) | |||
| Cash & Equivalents (End of Period) | $3.46 million | |||
| Total Debt (Current + Long-Term) | ~$53.6 million (Notes Payable + Line of Credit) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 6% in Q3 and 4% YTD compared to 2023. Management attributes this primarily to decreased U.S. recurring revenue from the existing client base, with 26-28% of the decline stemming from non-core solutions.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 7% in Q3 and 6% YTD, driven by lower marketing, legal, and consulting fees, partially offset by increased salaries for strategic leadership and product development.
- Interest Expense: Interest expense increased significantly (from $0.16M to $0.71M in Q3) due to higher borrowings on the Line of Credit and Delayed Draw Term Loan, as well as an increase in the interest rate on the Term Loan to a floating SOFR-based rate.
- Acquisition: The company acquired Nobl Health on July 15, 2024, for approximately $6.3 million (including contingent consideration). This added $4.6 million in goodwill and intangible assets.
Guidance, Outlook, and Risks
- Capital Allocation: The Board prioritizes funding innovation and growth (including M&A), followed by dividends and share repurchases. The company continues to invest in AI solutions and headquarters renovations.
- Debt Structure: In August 2024, the Credit Agreement was amended to extend maturities to May 2027 and convert the Term Loan to a floating rate (SOFR + 235 bps). The company has $25 million available on its Line of Credit and $39 million on its Delayed Draw Term Loan.
- Shareholder Returns: The company declared a quarterly dividend of $0.12 per share. It also repurchased 395,217 shares in Q3 under its 2022 Program, with 700,633 shares remaining authorized.
- Risks: Key risks include client contract non-renewal, competitive price pressure, the impact of global conflicts and economic downturns, and the ability to retain key personnel. The company notes that future interest expenses are expected to increase due to the amended debt terms.
Investor Verification Checklist
- Recurring Contract Value (RCV): Verify the trend in RCV, which declined 9% YTD to $131.6 million, indicating a lack of new contract growth to offset losses.
- Debt Covenants: Confirm continued compliance with the fixed charge coverage ratio (1.10x) and cash flow leverage ratio (3.00x), especially given the increased interest expense and working capital deficit of $23.6 million.
- Acquisition Integration: Monitor the performance of the Nobl Health acquisition and the realization of synergies, as well as the potential payout of the $1.0 million contingent consideration.
- Capital Expenditures: Track the $11.0 million spent on CapEx YTD, specifically the $2.5 million estimated for 2024 and $4.7 million for 2025 regarding headquarters renovations.
- Client Retention: Assess the stability of the core client base given the reported decline in recurring revenue from existing clients.